European regulators have given the green light for two of Merck & Co’s new drugs, licensing its anti-psychotic treatment Sycrest …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

